Cartherics appoints new Board Chair and Non-Executive Director
- Cartherics appoints Prof. Bryan Williams as new Board Chair and Ms. Laurence Nore as Non-Executive Director
Melbourne, Australia, 16 April 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company focused on developing immune cell therapies for cancer and other diseases, is pleased to announce the appointment of Prof. Bryan R.G. Williams as new Board Chair and Ms. Laurence Nore as Non-Executive Director as part of a strategic leadership transition.
Prof. Williams has been a Non-Executive Director at Cartherics since 2017 soon after the company’s inception and is an internationally recognised cancer researcher with considerable Board experience in both private and listed companies as well as research institutes and associations.
Prof. Williams, Chairman, Cartherics said: “I am very pleased to step up to Chair the Cartherics Board after serving as a Board member for the past several years. Cartherics has developed a strong patent portfolio, preclinical data and manufacturing processes developing allogeneic CAR-T and CAR-NK cells for treating ovarian cancer and endometriosis. I look forward to working with the Board and management as we move into the clinical phase of our development.”
Prof. Williams succeeds Mr. Bob Moses, Cartherics’ founding Chair, who has stepped down for personal reasons.
Ms. Laurence Nore is a seasoned business executive with over two decades of experience in the US Life Sciences industry, specialising in therapeutics and diagnostics. Her expertise spans business strategy, M&A, financial management, and partnership structuring, making her an invaluable asset to biotech company boards.
Ms. Nore, Non-Executive Director, Cartherics said: “I’m thrilled to be joining the Board of Cartherics, and I look forward to working with the other Directors and the management team to take the company to the next level and bring hope to patients with cancer, endometriosis and other devastating diseases globally.”
These Board appointments will support the Company’s growth trajectory, strengthen its strategic leadership position and expand its market presence.
Cartherics’ CEO, Prof. Alan Trounson AO said: “Bryan Williams is an international scientific expert in human cancer with strong ties to US institutions and Australasian biotechnology companies. His guidance as Board Chairman in the highly technical field of cancer therpies will be critical for the company’s success. The appointment of Laurence Nore as Non-Executive Director is especially important because of her European and American business experience in the field of medical biotechnology and will considerably strengthen the company’s potential to navigate the rapidly changing business, financial and regulatory challenges for delivering therapies for cancer and endometriosis.”
******
About Cartherics
Cartherics Pty Ltd is a privately held biotechnology company based in Melbourne, Australia that is rearming the body’s immune system to fight cancer, endometriosis and potentially Alzheimer’s Disease. It is developing cell-based immunotherapies for the treatment of cancer and endometriosis, with a portfolio of CAR-T and CAR-NK cell products. The Company’s allogeneic (“off-the-shelf”) cell platform is based upon induced pluripotent stem cells (iPSCs) generated from donated cord blood that can be differentiated into NK cells, T cells and other cells of the immune system. The iPSCs are genetically engineered at specific “safe harbour” genomic sites to provide enhanced function for the derived NK and other immune cells. The Company’s lead product, CTH-401, is a CAR-iNK cell product. It carries a CAR directed against TAG-72, a well-validated tumour target, along with the deletion of two genes associated with immunosuppression. The company has a strong pipeline of CAR-immune cell products tailored to disrupt ovarian cancer and endometriosis.
Media contact
Christine Filippis
Teraze Communications
Phone: +61 419 119 866
Email: christine@teraze.com.au
